Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The D-alanyl-D-alanine (D-Ala-D-Ala) motif is a critical structural component found at the C-terminus of the pentapeptide chain in peptidoglycan precursors, most notably Lipid II, in Gram-positive bacteria (PubMed, 2014). It serves as the essential substrate for penicillin-binding proteins (PBPs), which catalyze the cross-linking of the bacterial cell wall to provide mechanical stability and protect the cell from osmotic pressure. This motif is the primary therapeutic target for glycopeptide antibiotics, such as vancomycin, which bind to the dipeptide via a specific binding pocket. By sequestering the D-Ala-D-Ala terminus, these drugs sterically hinder the enzymes responsible for peptidoglycan polymerization and cross-linking, ultimately leading to cell wall weakening and osmotic lysis (StatPearls, 2023). Resistance to these drugs often arises through the modification of this motif to D-alanyl-D-lactate (D-Ala-D-Lac) or D-alanyl-D-serine (D-Ala-D-Ser), which significantly reduces antibiotic binding affinity (Journal of Biological Chemistry, 2014). Understanding this target is vital for treating serious infections caused by methicillin-resistant Staphylococcus aureus (MRSA) and other multi-drug resistant Gram-positive pathogens.
Glycopeptide antibiotics bind to the D-Ala-D-Ala C-terminus of the pentapeptide chain of Lipid II and nascent peptidoglycan via a network of five hydrogen bonds. This binding sterically inhibits the transglycosylation (polymerization) and transpeptidation (cross-linking) steps of cell wall synthesis, leading to the cessation of cell wall construction and subsequent bacterial cell death (StatPearls, 2023; Nature Reviews Microbiology, 2008).
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on D-alanyl-D-alanine terminus of peptidoglycan precursors (D-Ala-D-Ala).